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Abstract
Objective—Mucinous cystic neoplasms (MCNs) of the pancreas have often been confused with
intraductal papillary mucinous neoplasms. We evaluated the clinicopathologic characteristics,
prevalence of cancer, and prognosis of a large series of well-characterized MCNs in 2 tertiary
centers.
Methods—Analysis of 163 patients with resected MCNs, defined by the presence of ovarian
stroma and lack of communication with the main pancreatic duct.
Results—MCNs were seen mostly in women (95%) and in the distal pancreas (97%); 25% were
incidentally discovered. Symptomatic patients typically had mild abdominal pain, but 9%
presented with acute pancreatitis. One hundred eighteen patients (72%) had adenoma, 17 (10.5%)
borderline tumors, 9 (5.5%) in situ carcinoma, and 19 (12%) invasive carcinoma. Patients with
invasive carcinoma were significantly older than those with noninvasive neoplasms (55 vs. 44
years, P = 0.01). Findings associated with malignancy were presence of nodules (P = 0.0001) and
diameter ≥60 mm (P = 0.0001). All neoplasms with cancer were either ≥40 mm in size or had
nodules. There was no operative mortality and postoperative morbidity was 49%. Median follow-
up was 57 months (range, 4 –233); only patients with invasive carcinoma had recurrence. The 5-
year disease-specific survival for noninvasive MCNs was 100%, and for those with invasive
cancer, 57%.
Conclusions—This series, the largest with MCNs defined by ovarian stroma, shows a
prevalence of cancer of only 17.5%. Patients with invasive carcinoma are older, suggesting
progression from adenoma to carcinoma. Although resection should be considered for all cases, in
low-risk MCNs (≤4 cm/no nodules), nonradical resections are appropriate.
Mucinous cystic neoplasms (MCNs) usually are large, septated, thick-walled mucinous cysts
that lack communication with the ductal system, and occur almost exclusively in the
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tpancreatic body and tail of middle-aged women.1– 6 Histologically, they are characterized by
2 distinct histologic components: an inner epithelial layer composed of tall mucin-secreting
cells, and a dense cellular ovarian-type stroma. The latter was first described by Compagno
and Oertel in 1978, who made a clear distinction between these neoplasms and serous cystic
tumors.7 However, the presence of ovarian stroma was not considered a specific diagnostic
criterion for MCNs, and as a consequence, for many years MCNs and intraductal papillary
mucinous neoplasms (IPMNs) were frequently confused.1–14 It was not until 1996 that the
World Health Organization (WHO) clearly defined and distinguished IPMNs and MCNs,15
and not until 2000 when a new WHO classification emphasized the presence of ovarian
stroma in MCNs.4 More recently, at a consensus conference held in Sendai, Japan, the
International Association of Pancreatology put forward guidelines requiring the presence of
ovarian stroma to establish the diagnosis of MCNs.2
The distinction between MCNs and IPMNs is important in clinical practice. Lacking clear
diagnostic criteria, many series of MCNs were actually “contaminated” by IPMNs,
especially by branch-duct IPMNs.1–14 As our knowledge of pancreatic mucinous tumors has
increased, MCNs and IPMNs appear to be 2 distinct neoplasms, having different biologic
behavior and pathologic features, including prevalence of invasive cancer, recurrence rate
after radical resection, and presence of multifocal lesions.1– 4
The aim of this study is to analyze the combined experience of the Massachusetts General
Hospital (MGH) and the University of Verona (UV) with resected MCNs defined by the
presence of ovarian stroma to elucidate their specific demographic and clinicopathological
characteristics, as well as their long-term outcomes.
PATIENTS AND METHODS
The MGH and UV Institutional Review Boards approved this study. Patients who underwent
pancreatic resection between January 1988 and October 2005 for pathologically confirmed
MCNs were identified from prospectively collected databases. Both presence of ovarian
stroma and lack of communication with the main pancreatic duct were used as criterion to
distinguish MCNs from IPMNs.2,4
In the study period, 567 patients underwent surgery for mucinous tumors of the pancreas
(305 MGH and 262 UV). Of these 163 (29%), 102 from UV and 61 from MGH, were
determined to have MCNs, whereas the remaining patients had main-duct, branch-duct, or
combined IPMNs, or indeterminate mucinous neoplasms. Information including
demographics, clinical history, diagnostic work-up, type of surgery, postoperative course,
pathology, and long-term follow-up were recorded. Perioperative mortality was defined as
in-hospital or 30-day death.
Tumors were classified according to the WHO criteria as MCNs with mild dysplasia
(adenoma), with moderate dysplasia (borderline neoplasm), with high-grade dysplasia
(carcinoma in situ), and MCN with invasive carcinoma.4 In short, in MCN adenoma, the
epithelium shows basally located nuclei with no increase in mitosis. In the borderline
MCNs, the epithelium may exhibit papillary projections or crypt-like invagination, some
nuclear pseudostratification with crowding and slightly enlarged nuclei. Mitoses can be
observed. MCN with noninvasive carcinoma demonstrate high-grade dysplastic epithelial
changes. The epithelium often forms papillae and irregular budding, as well as branching
with nuclear stratification, severe nuclear atypia, and frequent mitoses.
MCNs with invasive carcinoma were characterized by the presence of malignant neoplastic
cells beyond the epithelial lining of the cyst,1,4 and 2 degrees of invasion were defined: (1)
intracapsular, if neoplastic invasion did not go beyond the outer layer of the wall; (2)
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textracapsular, if it extended into the surrounding pancreatic and extrapancreatic tissue.1 For
the analysis MCNs with adenoma or borderline neoplasms were grouped as “benign,” and
MCNs with carcinoma in situ and invasive carcinoma as “malignant.”
Follow-Up
All patients had periodic follow-up evaluations consisting of clinical examination, blood
tests including fasting glucose levels, and imaging procedures such as contrast-enhanced
abdominal ultrasound, computer tomography, or magnetic resonance imaging. Recurrences
were confirmed histologically whenever possible. Most patients with benign MCNs had
yearly follow-up evaluation for the first 5 years, whereas patients with invasive carcinoma
were seen every 6 months for the first 2 years and yearly thereafter.
Worsening diabetes was defined as deterioration in the metabolic control of previously
diagnosed diabetes requiring modification of the medical treatment. No specific exocrine
function tests were performed. New onset of exocrine insufficiency was defined as
steatorrhea and weight loss requiring pancreatic enzyme supplementation.
Statistical Analysis
Statistical analysis was performed with the SPSS statistical software package (SPSS,
Chicago, Ill). Results are presented as median (range). Categorical variables were compared
using a Pearson χ 2 test and Fisher exact test when cell counts were <5. Normally distributed
continuous variables were compared using a 2-sample Student t test; the Mann-Whitney U
test was used for non-normally distributed variables. Survival analysis was done using the
Kaplan-Meier function, comparing patients with different histotype with the log rank test. A
P value of less than 0.05 was considered statistically significant.
RESULTS
Of the 163 patients with resected MCNs, 118 had adenoma (72%), 17 borderline neoplasms
(10.5%), 9 carcinoma in situ (5.5%), and 19 invasive carcinoma (12%). Invasive carcinoma
was intracapsular in 13 cases (8%) and extracapsular in 6 (4%). One hundred thirty-five
(82.5%) patients had benign MCNs (adenoma and borderline), and 28 (17.5%) malignant
MCNs (carcinoma in situ and invasive carcinoma).
Demographic and Clinical Presentation
Demographic and clinical characteristics are shown in Table 1. Most patients with MCNs
were middle-aged women. Only 8 male patients were identified in this series (5%), and they
were significantly older than their female counterparts (63 vs. 44 years, P = 0.011). No
statistically significant differences were found when comparing the age of the 28 patients
with malignant tumors (carcinoma in situ and invasive carcinoma) with those with benign
tumors (49.5 vs. 44 years, P = 0.129); however, patients with invasive carcinoma alone were
significantly older than those with noninvasive neoplasms (55 vs. 44 years, P = 0.01).
Fourteen (8.6%) patients, (10 with benign and 4 with malignant MCNs), had had previous
surgery. In 11 of these, MCNs were misdiagnosed as pseudocysts, and had undergone
cystjejunostomy or cystgastrostomy. In these cases, the correct diagnosis was not reached
until a mean of 77 ± 32 (SD) months from the initial surgery.
Overall, 118 patients (72.5%) were symptomatic, complaining mostly of mild or vague
abdominal pain. Fifteen patients (9%) presented with acute pancreatitis. There was a
nonsignificant higher incidence of abdominal pain in patients with benign tumors and of
weight loss, fatigue, and diabetes in those with cancer.
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Twenty-three patients (14%) had a history of previous (n = 20) or metachronous (n = 3)
neoplasms. They were 21 females and 2 males, and they were significantly older than the
remaining patients (51 vs. 43 years, P = 0.01). Of 155 female patients 10 (6.5%) had breast
carcinoma (mean age ± SD at breast cancer diagnosis: 51 ± 9 years), diagnosed before
pancreatic MCNs in 9 cases; of those patients with breast cancer, 2 also had papillary
thyroid carcinoma, and 1 renal cell carcinoma. Two additional patients had breast
fibroadenoma and 3 ovarian neoplasms (2 mucinous cystadenoma and 1 unspecified
carcinoma).
Tumor Location and Size
Anatomic locations and radiologic features are reported in Table 2. Practically all MCNs
were located in the body-tail of the pancreas (97%). Lesions were in the pancreatic head in
only 5 patients. No patient had multifocal MCNs or neoplasms located in the uncinate
process. The median diameter of the lesions, as determined by preoperative imaging, was 50
mm, and was significantly larger in malignant neoplasms (82.5 vs. 45 mm, P = 0.001). All
malignant MCNs were located in the body or tail of the pancreas.
Surgical Procedures
In keeping with MCNs anatomic location, the most common surgical procedure was a distal
pancreatic resection, performed in 153 cases (94%). Standard distal pancreatectomy (DP)
with splenectomy was carried out in 119 patients (73%), spleen-preserving DP in 28 (17%)
and an extended DP in 6 (4%). Other surgical resections included 4 (2.5%)
pancreaticoduodenectomies, 5 (3%) atypical resections (3 enucleations and 2 middle
pancreatectomies), and 1 total pancreatectomy for a large MCN involving almost the entire
gland. Fourteen patients (8.5%) underwent laparoscopic DP, with splenic preservation in 4
cases.
Operative Outcomes
There was no mortality in this series of 163 patients, although overall postoperative
morbidity was 49%. Postoperative complications for the entire cohort, as well as the
comparison of patients treated at MGH or at UV, are described in Table 3. The rate of
postoperative complications was almost the same in the 2 Institutions. The postoperative
hospital stay was longer at UV, but the rate of readmission was higher at MGH. Seven
(4.5%) patients required reoperation because of intra-abdominal collections (n = 5), bleeding
(n = 1), or splenic infarction after spleen-preserving DP (n = 1).
Pathology
The pathologic characteristics of the tumors are shown in Table 4. Multiple samples were
obtained from neoplastic tissue and surrounding non-neoplastic tissue. A mean of 16 slides
(range, 3–94) were examined per patient. The median diameter, as evaluated by the
pathologist, was 50 mm (mean ± SD: 55 ± 30; range, 8–150), and benign neoplasms were
significantly smaller than malignant ones (median, 45 vs. 80 mm; mean ± SD: 50 ± 28 vs.
83 ± 25; P = 0.0001). Pathologic examination confirmed the absence of multifocal lesions in
all specimens.
Significant factors associated with malignancy were the presence of nodules (P = 0.0001)
and a diameter equal to or greater than 60 mm (P = 0.0001). Nodules were identified in 6 of
118 (5%) adenomas, in none of 17 borderline tumors, in 2 of 9 carcinomas in situ (22%),
and in 16 of 19 invasive carcinomas (84%). The presence of septae and epithelial denudation
were not significantly different between benign and malignant MCNs. Figure 1 is a scatter
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tplot of radiologic tumor size as a function of histotype and nodules. All neoplasms with
cancer were either greater than 40 mm in size or had nodules.
Data on lymph nodes status were not available in 2 patients with invasive carcinoma. None
of the remaining 17 patients with invasive carcinoma had positive lymph nodes; the mean
number of resected nodes in this subgroup was 14. Of the 19 patients with invasive
carcinoma, microvascular and perineural invasion were present in 2 (10.5%) and 3 (16%)
patients, respectively. Five (26%) patients had extracapsular neoplastic invasion, and the
other 14 (74%) intracapsular. In 7 cases (37%) the invasive component was focal, with
limited invasion of the stroma. Among patients with invasive cancer, only 1 had a lesion
with diameter ≤40 mm, as well as a nodule (Fig. 1). In this patient the cancer was
intracapsular and only focally invasive.
Long-Term Follow-Up and Survival
Follow-up with a median duration of 57 months (mean ± SD: 71 ± 54; range, 4 –204) was
available in 97% of patients.
Seven patients (4.5%) developed tumor recurrence after a mean of 32.5 months (range, 4 –
99). All these patients had invasive carcinoma at the initial resection, accounting for a
recurrence rate of 37% in the invasive cancer subgroup. Four patients had carcinoma with
extracapsular invasion and 3 had intracapsular growth but with diffuse infiltration of the
stroma. No patient with focally invasive carcinoma developed recurrence (P = 0.017). The
recurrence was intraperitoneal in 2 patients, and distant (liver metastases) in 5.
All patients with tumor recurrence died of disease after a mean of 6.5 months (range, 2–17),
and another 7 patients died during follow-up for other causes.
Overall, 12 (7.5%) patients developed new onset of exocrine insufficiency requiring oral
enzyme supplements, and 37 (22.5%) developed new onset (n = 30) or worsening (n = 7)
diabetes. The development of both exocrine and endocrine insufficiency was higher in
patients with malignant neoplasms [exocrine insufficiency: 21.5% vs. 4.5% (P = 0.007);
endocrine insufficiency: 43% vs. 18.5% (P = 0.005)].
Overall 5- and 10-year actuarial survival for the entire series was 93% and 84%, respectively
(Fig. 2). The 5-year disease-specific survival for noninvasive MCNs was 100%, and for
those with invasive cancer 57% (Fig. 3).
DISCUSSION
The pancreas has been known to harbor neoplastic cysts since the 19th century, but for more
than a century these were referred to simply as cystadenomas and
cystadenocarcinomas.12,13,17,18 It was not until 1978 that Compagno and Oertel more
clearly characterized these lesions, made a distinction between serous and mucinous
cystadenomas, and emphasized the benign course of serous and the malignant potential of
mucinous lesions.7 A few years later Ohashi et al made the first description of what now we
refer to as IPMNs,19 although it took another decade for wide recognition of this tumor.2 For
these reasons, many patients with IPMN in the past were wrongly diagnosed as MCNs. Even
through most of the 1990s, the distinction between MCNs and branch-duct IPMNs was not
apparent, because IPMNs were thought to be a disease mainly affecting the main pancreatic
duct.12,20,21 It was not until 1996 and later on in 2000,4,15 that the WHO classified IPMNs
and MCNs as 2 distinct diseases. However, even subsequently, many reports continued not
to require ovarian stroma as a diagnostic criterion for MCNs. As a result, there has been
significant confusion in the analysis of these 2 entities.6,8,11–14 To complicate the situation
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tfurther, the ovarian stroma can be partially fibrotic, hypocellular, and identifiable in only a
few areas1; many series of MCNs did not even describe the percent of neoplasms with this
characteristic.1,8
A review of the most important series of MCNs reported in the literature shows wide
discrepancy in the clinical characteristics and malignancy rates (Table 5). When the WHO
definition of MCNs is applied (group A), these neoplasms have unique characteristics:
lesions are found almost exclusively in the distal pancreas of middle-aged women, and the
rate of invasive cancer is generally low.1,3,6 The present series, which is the largest cohort of
MCNs defined by presence of ovarian stroma reported in the literature to date, confirms
these findings. We found that 95% of the patients were women with a median age of 45
years, and that 97% of the lesions were seen in the distal pancreas. Our data also show that a
single MCN can harbor different degrees of dysplasia, form adenoma to invasive carcinoma.
The prevalence of invasive cancer was only 12%, which is less than previously
reported.1,3,5,10 However, the average size of our tumors (5.5 cm) was much smaller than
the series published by Thompson et al (10.5 cm)5 and Zamboni et al (8.4 cm),1 and more in
line with the series of Reddy et al, who reported prevalence of invasive cancer of 7% and an
average tumor size of only 5 cm.3 In our experience, the proportion of adenomas in MCNs
(72%) is much higher than in IPMNs (46% in branch-duct IPMN, and 12% in main-duct
IPMN), and conversely the rate of overall malignancy was less (17.5% in MCNs, 22% in
branch-duct IPMNs, and 60% in main-duct IPMNs).21,22
In those series in which the presence of ovarian stroma is not considered a prerequisite to
diagnose MCNs (group B of Table 5), patients are older; there is a higher proportion of
males; and the lesions are more often located in the head.8,11–14 Wilentz et al8 reported that,
of 20 patients with invasive carcinoma, 45% were male, the median age was 60 years, and
63% of lesions were in the proximal pancreas, which is much more likely the profile of
IPMNs rather than MCNs. In doubtful cases (absence of ovarian stroma but no demonstrable
communication with the main duct), it is better to classify these mucinous lesions as
“indeterminate,” rather than to include them with MCNs.2
The observation that MCNs of the pancreas predominantly affect women is in keeping with
the fact that MCNs of the liver and retroperitoneum are also diagnosed mainly in
females23–27 and that MCNs can frequently be seen in ovaries28,29 but rarely in the testis.30
Zamboni et al1 suggested that pancreatic MCNs may develop from endodermal immature
stroma stimulated by female hormones31 or from primary yolk cells implanted in the
pancreas during embryogenesis.32 The expression of estrogen receptors in MCNs also
supports the putative role of female hormones in pathogenesis.6,9
In the present series MCNs presented with a wide variety of symptoms, but 27.5% were
asymptomatic. No individual symptom was significantly associated with a likelihood of
malignancy. Sixty percent of patients complained of mild and vague abdominal pain, which
was more frequent in benign than in malignant neoplasms. Interestingly, 9% of patients had
acute pancreatitis, which is probably due to compression with extrinsic obstruction of the
pancreatic duct by large MCNs. Fatigue, weight loss, palpable abdominal mass, and diabetes
were more likely associated with malignant MCNs, but because of the low prevalence of
these symptoms this was not statistically significant.
One interesting finding of this study is a seemingly high rate of extrapancreatic neoplasms in
patients with both benign (14%) and malignant (14.5%) MCNs. In particular we found a
prevalence of breast carcinoma of 6.5%, which is greater than the 4.2% expected rate in the
general population in this age group,33 although this could be related to increased
surveillance in patients with a prior diagnosis of neoplasm. In this series no patient had a
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thistory of previous pancreatic tumor, although IPMNs have been reported to be associated
with pancreatic cancer or endocrine tumors of the pancreas.34,35 Moreover in IPMNs the
prevalence of extrapancreatic neoplasms is higher than in MCNs, ranging from 27% to
39%.2,36 These may represent further differences between MCNs and IPMNs.
Patients with malignant tumors were found to be 5.5 years older than those with adenoma
and borderline neoplasms, and patients with invasive carcinoma were 11 years older than
those with noninvasive MCNs (P = 0.01). Sarr et al14 and Zamboni et al1 have also reported
similar data. Moreover, MCNs with invasive carcinoma frequently contain areas of
adenoma, borderline neoplasm, and carcinoma in situ. These findings suggest that benign
MCNs may progress to malignancy,2 although the low prevalence of invasive carcinoma
indicates a lesser biologic aggressiveness of MCNs and that malignant transformation may
not be inevitable in all patients.
Areas of denudation of the epithelial lining were a common finding both in benign and
malignant MCNs, especially in large lesions. Extensive denudation as well as the possible
coexistence of different degrees of dysplasia makes thorough sampling of MCNs essential to
detect even small foci of invasive carcinoma.1,3 In this study a mean of 16 slides (range, 3–
94) was examined per patient.
An unexpected observation in this cohort is the complete absence of lymph node metastases
in patients with invasive carcinoma, despite sampling of an average of 14 nodes in 17 of 19
patients. No specific data with regard to node status are mentioned in previous reports of
MCNs defined by ovarian stroma.1,3,5 This represents a crucial difference with respect to
IPMNs, in which lymph node metastases are present in 30% to 46% of invasive main-duct
IPMNs,2,21,37 and, in our experience, in 19% of invasive branch-duct lesions.22
Interestingly, ovarian mucinous neoplasms show a similar biologic behavior, with distinctly
different clinicopathologic characteristics compared with other ovarian histotypes.28,38,39
Ovarian mucinous carcinomas usually spread to the peritoneum and to other organs through
the bloodstream, but lymph node metastases are reported in less than 10% of the cases.16,40
Another observation of the present series is the strong correlation between larger size and
nodules with malignancy: 92% of malignant MCNs were either equal to or greater than 60
mm in size, and 64% of them had nodules. No cancer was diagnosed in neoplasms less than
40 mm in size unless nodules were present. There were also no cases of multifocal MCNs.
One of the important findings of this study is that no patient with adenoma, borderline
neoplasm, or carcinoma in situ had a recurrence after a median follow-up of 57 months:
their 5-year disease-specific survival is 100%. The actuarial 5-year survival for patients with
invasive cancer is 57%, which is similar to that reported in invasive main-duct (60%) and
branch-duct (63%) IPMNs, but much higher than that of ductal adenocarcinoma of the
pancreas. Although the number of patients with invasive carcinoma is small (19 cases), our
data suggest that only patients with invasive cancer diffusely invading into or beyond the
tumor wall are at substantial risk of distant or local recurrence, whereas those with
intracapsular foci of invasive carcinoma have a much better prognosis (in fact none of these
patients had a recurrence). Unfortunately, once recurrence is diagnosed, the prognosis is
very poor: all patients died after a mean of 6.5 months from the diagnosis of recurrence.
Reddy et al3 proposed nonoperative management for small (<3 cm) MCNs without mural
nodules, especially in elderly patients with comorbidities. We agree that in such cases
nonoperative management can be considered because our data show that all MCNs <4 cm
with no nodules were either adenoma or borderline neoplasms. However, our age
distribution indicates that such patients are very uncommon: in this series only 3 patients
older than 70 years had tumors that were less than 4 cm and with no nodules. Because most
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tpatients with MCNs are middle-aged women with a long life expectancy, nonoperative
management based on periodic computer tomography scan or magnetic resonance imaging
would require years of careful follow-up with imaging at high cost. Because patients with
invasive carcinoma were significantly older (by 11 years) than those with noninvasive
MCNs, and MCNs with invasive cancer frequently contain areas of adenoma, borderline
neoplasms, or carcinoma in situ, we believe that benign MCNs can progress to invasive
carcinoma. It is also likely that some of these lesions could remain as adenomas. Because at
present we are unable to identify those that will progress, our recommendation is to resect
all MCNs, regardless of size, in patients who are fit candidates for surgery. This is in
agreement with the recommendations of the International Association of Pancreatology in
the Sendai consensus.2
The great majority of MCNs are located in the body or tail of the pancreas, and are therefore
amenable to DP, which is a safe procedure in high-volume centers.41– 43 Because the
probability of malignancy is very low in patients with small MCNs without nodules,
lymphadenectomy can be avoided and parenchyma-sparing procedures such as middle
pancreatectomy44 and perhaps enucleations45,46 should be performed more often, because
they decrease the rate of postoperative pancreatic insufficiency and they have been proven to
be safe in the treatment of well-selected patients with MCNs.44,47 If tumors are removed
when they are smaller, the expected loss of pancreatic parenchyma should be low, thus
decreasing the probability of developing endocrine and exocrine insufficiency during
follow-up.47
When these operations are not feasible because of tumor location and/or size, spleen-
preserving or limited DP is a valid alternative.48,49 In small neoplasms (<5 cm) a minimally
invasive approach should be considered. Recent experiences from high-volume centers show
that laparoscopic resection of neoplasms in the body and tail of the pancreas is feasible and
safe in patients with benign tumors, and this approach can shorten the postoperative hospital
length of stay, increase the rate of spleen-preserving DP, and minimize the cosmetic impact
of the surgical wound.50 –52
Finally, considering the relatively low frequency of MCNs, the importance of distinguishing
MCNs from IPMNs, and the improved surgical outcomes for pancreatic resections in high-
volume hospitals, we believe that patients with MCNs should preferentially be managed in
specialized centers.
CONCLUSIONS
MCNs defined by the presence of ovarian stroma are a distinct entity with characteristic
demographics and clinicopathologic features. The prevalence of invasive cancer is low
(12%), and in noninvasive tumors surgery is routinely curative, with no recurrence during
follow-up. MCNs have a low biologic aggressiveness, and notably no lymph node
metastases were found in invasive cancer. Although the prognosis of MCNs with invasive
cancer is much better than ductal adenocarcinoma and is comparable to that of patients with
invasive IPMNs, all patients who had recurrence died soon after diagnosis. The 11-year
difference in age between patients with invasive versus noninvasive MCNs supports the
hypothesis of transformation from benign MCNs to invasive carcinomas. For these reasons,
and considering the relatively young age and long life expectancy of these patients, resection
remains the treatment of choice. In small MCNs without nodules, parenchyma/spleen-
sparing and minimally invasive procedures are preferable.
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tFIGURE 1.
Scatter plot of radiologic tumor size as a function of histologic subtype, and presence of
nodules.
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tFIGURE 2.
Overall 5- and 10-year actuarial survival for the entire series (n = 163) was 93% and 84%,
respectively.
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The 5-year disease-specific survival was 100% for patients affected by adenoma, borderline
neoplasm, or carcinoma in situ (black line), and 57% for those with invasive carcinoma
(hatched line).
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TABLE 3
Surgical Complications and Postoperative Course in 163 Patients Who Underwent Pancreatic Resections for
MCN
Total (n = 163) University of Verona (n = 102) MGH (n = 61) P (MGH vs. UV)
Overall morbidity (%) 81 (49) 51 (50) 30 (49) NS
Abdominal (%) complications* 54 (33) 33 (32.5) 21 (34.5) NS
Overall pancreatic fistula (%) 39 (24) 26 (25.5) 13 (21) NS
Grade B–C pancreatic fistula† (%) 15 (9) 12 (12) 3 (5) NS
Intra-abdominal (%) collections/abscess 19 (12) 12 (12) 7 (11.5) NS
Extra-abdominal (%) complications 39 (24) 30 (29.5) 9 (15) 0.025
Perioperative readmission (%) 12 (7.5) 4 (4) 8 (13) 0.033
Need for interventional radiology (%) 13 (8) 9 (9) 4 (6.5) NS
Reoperation (%) 7 (4.5) 5 (5) 2 (3.5) NS
Mortality 0 0 0
Postoperative stay (median), d 9 10 7 0.001
*
Abdominal complications is defined as the occurrence of a pancreatic or biliary fistula, abscess, collection, hemorrhage or delayed gastric
emptying using previously defined criteria.
†
According to the pancreatic fistula classification by the International Study Group on pancreatic fistula.43
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TABLE 4
Pathological Characteristics of 163 MCNs
Benign (n = 135) Malignant (n = 28) Total (n = 163) P (Benign vs. Malignant)
Size >60 mm (%)* 41 (30) 24 (92)* 65 (40.5)* 0.0001
Presence of denudation >50%† (%) 55 (40.7) 13 (46.4) 68 (41.7) NS
Presence of nodules/papillae (%) 6 (4.4) 18 (64.3) 24 (14.7) 0.0001
Presence of macroscopic septae (%) 50 (37) 12 (42.9) 62 (38) NS
Single lesions (%) 135 (100) 28 (100) 163 (100)
Median size (mm)* 45 (8–150) 80 (20–130) 50 (8–150) 0.0001
*
Tumor size was not available in 2 specimens.
†
Denudation was defined as lack of lining epithelium in the cyst wall.
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